Stock listing

NASDAQ:ADIL Adial Pharmaceuticals, Inc Stock

Home listing (NASDAQ) of Adial Pharmaceuticals, Inc

Follow Adial Pharmaceuticals, Inc into a list and get an email when it puts out news.

Share price · NASDAQ:ADIL

$4.05 USD -0.10 (-2.4%)

Close on Nov 4, 2026

Past year +29.8% · daily closes, Feb 6, 2026 – Nov 4, 2026, adjusted for splits
Day range
$3.95 – $4.30 USDNov 4, 2026
Volume
7,035 sharesNov 4, 2026
Market cap
$10.63M USDAt the close on Nov 4, 2026 · price × 2.63M shares outstanding
Traded on an average day
$270,267 USDMedian day 48,050 shares · last 3 months, Aug 4, 2026 – Nov 4, 2026
Adial Pharmaceuticals, Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ADIL · Home$4.05 USD-0.10 (-2.4%)7,035$3.95$4.30$3.945$4.15Close on Nov 4, 2026

Daily closes

Last 3 months, Aug 4, 2026 – Nov 4, 2026 · NASDAQ:ADIL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.05-0.10-2.4%$3.95$4.30$3.9457,035
$4.15+0.26+6.7%$4.07$4.39$3.6833,132
$3.89+0.08+2.1%$4.70$4.83$3.80243,497
$3.81-1.07-21.9%$4.71$4.94$3.02169,247
$4.88-0.17-3.4%$4.50$4.97$3.67146,921
$5.05+1.34+36.1%$3.98$5.15$3.8099,654
$3.71+0.03+0.8%$3.72$3.98$3.677,357
$3.68-0.24-6.1%$3.94$3.94$3.5911,696
$3.92-0.30-7.1%$4.15$4.28$3.9247,359
$4.22+0.11+2.7%$4.16$4.22$4.162,300
$4.11+0.29+7.6%$3.75$4.41$3.7521,500
$3.82+0.20+5.5%$3.51$3.98$3.518,400
$3.62+0.13+3.7%$3.54$3.66$3.4612,100
$3.49+0.35+11.1%$3.07$3.66$3.0756,400
$3.14+0.14+4.7%$3.00$3.30$3.0013,900
$3.00-0.29-8.8%$3.17$3.32$3.0027,400
$3.29-0.21-6.0%$3.52$3.87$3.2075,400
$3.50-0.40-10.3%$4.04$4.04$3.47167,000
$3.90-0.07-1.8%$4.03$4.06$3.903,000
$3.97-0.02-0.5%$4.02$4.05$3.924,900
$3.99+0.01+0.3%$3.91$4.09$3.914,400
$3.98-0.37-8.5%$4.38$4.50$3.9811,900
$4.35+0.23+5.6%$4.05$4.43$3.9260,000
$4.12-0.01-0.2%$4.13$4.66$3.9264,500
$4.13+0.12+3.0%$4.12$4.45$3.8613,400
$4.01-0.14-3.4%$4.16$4.29$3.9535,300
$4.15+0.11+2.7%$4.04$4.30$3.9729,300
$4.04-0.18-4.3%$4.05$4.30$3.8547,500
$4.22-0.22-5.0%$4.40$4.56$4.1233,200
$4.44+0.40+9.9%$4.00$4.64$4.0047,300
$4.04-0.16-3.8%$4.25$4.25$3.7760,900
$4.20-0.20-4.5%$4.40$4.42$4.1440,200
$4.40-0.46-9.5%$4.82$4.82$4.2343,700
$4.86-0.35-6.7%$5.23$5.23$4.5986,900
$5.21-0.03-0.6%$5.25$5.38$5.0421,600
$5.24+0.24+4.8%$5.01$5.30$5.0029,700
$5.000.000.0%$5.02$5.18$4.8029,000
$5.00+0.10+2.0%$4.94$5.18$4.8746,500
$4.90-1.10-18.3%$6.06$6.11$4.80108,500
$6.00+0.07+1.2%$5.94$6.22$5.9017,200
$5.93-0.72-10.8%$6.64$6.65$5.8748,700
$6.65-0.47-6.6%$7.01$7.20$6.3367,600
$7.12+0.46+6.9%$6.61$7.20$6.2750,100
$6.66+0.34+5.4%$6.32$6.80$6.2552,800
$6.32+0.37+6.2%$5.92$6.43$5.8053,800
$5.95+0.20+3.5%$5.80$6.17$5.5144,400
$5.75+0.15+2.7%$5.57$5.98$5.3069,900
$5.60-0.09-1.6%$5.70$5.79$5.4563,500
$5.69-0.25-4.2%$5.96$5.96$5.4553,600
$5.94+0.12+2.1%$5.84$6.07$5.5964,600
$5.82+0.42+7.8%$5.35$5.90$5.1932,100
$5.40-0.82-13.2%$6.19$6.19$4.70132,300
$6.22+0.32+5.4%$5.95$6.41$5.7481,700
$5.90+0.14+2.4%$5.81$5.94$5.3642,000
$5.76+0.31+5.7%$5.44$5.80$5.4183,800
$5.45+0.46+9.2%$4.82$5.55$4.73125,800
$4.99+1.01+25.4%$3.84$5.08$3.84146,000
$3.98-0.41-9.3%$4.11$4.37$3.9848,600
$4.39+0.08+1.9%$4.35$4.64$4.2652,000
$4.310.000.0%$4.36$4.49$4.1164,800
$4.31+0.10+2.4%$4.16$4.493$4.0120,446
$4.21+0.23+5.8%$3.89$4.35$3.8953,256
$3.98-0.82-17.1%$4.80$4.87$3.70100,600
$4.80+0.75+18.5%$4.07$4.99$4.07178,700
$4.05+0.25+6.6%$3.75$4.20$3.75116,600
$3.80+0.16+4.4%$3.64$3.94$3.54122,100
Ticker
NASDAQ:ADIL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Adial Pharmaceuticals, Inc news

Adial Pharmaceuticals, Inc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 143 in all · newest Oct 28, 2026 · oldest 2020
Decks
26 decks · latest October 2026

Where Adial Pharmaceuticals, Inc is listed

ListingExchangeCountryCurrency
NASDAQ:ADIL · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ADILBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 4, 2026

Enterprise value
−$11.41M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.52

Biotechnology: the 10 companies nearest in size, of 891 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Adial Pharmaceuticals, Inc · NASDAQ:ADILUS$10.63M−US$11.41Mn/an/an/an/an/an/a1.52
Psyence Biomedical Ltd. · NASDAQ:PBMUS$11.33MUS$4.18Mn/an/an/a0.9×n/a0.0×0.90
Medicenna Therapeutics Corp. · TSX:MDNAUS$11.26MUS$7.37Mn/an/an/a9.7×n/a0.1×1.36
Shaperon Inc. · KRX:378800US$11.12M−US$8.17Mn/a−33.9×n/a0.8×n/a0.0×n/a
Miro Sciences Ltd · ASX:MSXUS$11.09MUS$8.03Mn/an/an/a1.1×n/a0.0×n/a
Fractyl Health, Inc. · NASDAQ:GUTSUS$10.88M−US$20.64Mn/an/an/an/an/an/a1.78
TME Pharma N.V. · EURONEXT:ALTMEUS$10.76MUS$12.80Mn/an/an/an/an/an/an/a
PharmAla Biotech Holdings, Inc. · CSE:MDMAUS$10.76MUS$10.59Mn/a12.0×n/a7.9×−126.9%0.0×0.38
Anebulo Pharmaceuticals, Inc. · OTC:ANEBUS$10.60MUS$1.56Mn/an/an/a1.3×n/a0.0×-0.01
IRLAB Therapeutics AB Class A · OMXSTO:IRLAB_AUS$10.60MUS$9.62Mn/a1.2×n/a1.1×−67.9%0.3×n/a
Ceryvyn Therapeutics Limited · ASX:CYVUS$9.96M−US$9.91M0.1×−14,971×n/a0.5×n/a0.0×n/a
Median of the othersUS$10.82MUS$5.77M0.1×−16.3×1.1×−97.4%0.0×0.90

Forecasts

Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
8.33 USD · Analysts' mean
EPS, year to Dec 2026
-1.05 · 1 analyst

Team and board

OfficerRole
Celia EconomidesChief Financial Officer
David RubensteinChief Scientist

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026
Q2 2026Aug 14, 2026 · After close+25.4%
Q1 2026May 8, 2026 · After close+0.7%
Q4 2025Mar 26, 2026−5.2%
Q3 2025Nov 13, 2025 · After close
Q2 2025Aug 13, 2025 · After close
Q1 2025May 14, 2025 · After close
Q4 2024Mar 31, 2025 · After close
Q3 2024Nov 13, 2024 · After close
Q2 2024Aug 13, 2024 · After close
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 1, 2024 · After close
Q4 2023Feb 20, 2024 · After close
Q3 2023Nov 14, 2023 · After close
Q2 2023Aug 21, 2023 · Before open
Q1 2023May 12, 2023 · After close
Q4 2022Mar 30, 2023 · After close
Q3 2022Nov 14, 2022 · Before open
Q2 2022Aug 15, 2022 · Before open
Q1 2022May 16, 2022 · Before open
Q4 2021Mar 28, 2022 · After close

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (October 2026)Merger or acquisition25 slidesOctober 2026
Merger or Acquisition (June 2026)Merger or acquisition26 slidesJune 2026
Investor Presentation (February 2026)Investor deck18 slidesFebruary 2026
Investor Presentation (January 2026)Investor deck18 slidesJanuary 2026
Investor Presentation (June 2025)Investor deck20 slidesJune 2025
Investor Presentation (January 2025)Investor deck27 slidesJan 13, 2025
Investor Presentation (January 2025)Investor deck20 slidesJanuary 2025
Investor Presentation (November 2024)Investor deck19 slidesNovember 2024
Investor Presentation (June 2024)Investor deck22 slidesJune 2024
Investor Presentation (May 2024)Investor deck23 slidesMay 2024
All 26 decks
DeckKindSlidesDate
Investor Presentation (February 2024)Investor deck23 slidesFebruary 2024
Investor Presentation (November 2023)Investor deck26 slidesNovember 2023
H.C. Wainwright Global Investment Conference 2023Conference26 slidesSep 11, 2023
Jefferies Healthcare Conference 2023Conference28 slidesJun 9, 2023
Investor Presentation (April 2023)Investor deck30 slidesApril 2023
Investor Presentation (March 2023)Investor deck9 slidesMar 7, 2023
Investor Presentation (August 2022)Investor deck28 slidesAugust 2022
Investor Presentation (May 2022)Investor deck28 slidesMay 2022
Investor Presentation (January 2022)Investor deck28 slidesJanuary 2022
Investor Presentation (April 2019)Investor deck23 slidesApr 30, 2019
IPO Roadshow (February 2019)IPO roadshow23 slidesFeb 13, 2019
Investor Presentation (September 2018)Investor deck23 slidesSep 24, 2018
IPO Roadshow (July 2018)IPO roadshow30 slidesJul 10, 2018
IPO Roadshow (November 2017)IPO roadshow30 slidesNov 27, 2017
IPO Roadshow (October 2017)IPO roadshow29 slidesOct 25, 2017
IPO Roadshow (September 2017)IPO roadshow29 slidesSep 28, 2017

Open Decks

Financings

RaiseDate
Private placement of prefunded warrants
Update: about US$32M
Buyers: Coastlands Capital (led the financing); Boxer Capital Management; Stonepine Capital Management; AuGC BioFund; Kern Capital
Insiders: Insiders and management participated
Use of proceeds: Fund operations into 2028, including IND-enabling studies and initiation of the Phase 1 trial of AT177 in ulcerative colitis
Oct 28, 2026
Private placement of pre-funded warrants and common warrants
Tranche closed: US$32M raised · US$2.7489 a share · common warrants to purchase up to 11,780,948 shares of common stock, sold with… · Lucid Capital Markets +1
Dealers: Lucid Capital Markets (lead), TD Cowen
Buyers: Coastlands Capital (led the financing); Boxer Capital Management; Stonepine Capital Management; AuGC BioFund; Kern Capital (one of the lead investors)
Insiders: insiders and management participated
Use of proceeds: Advance its lead colon-targeted AhR program through key clinical milestones
Jun 16, 2026
Warrant exercise of series C-1 and Series E warrants exercised for common stock
Announced: about US$2.86M · US$0.31 a share · Warrants at US$0.31 for 24 months · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners
Buyers: existing healthcare-focused institutional investor (exercising the Existing Warrants for approximately $2.86 million)
Use of proceeds: Working capital and other general corporate purposes
Nov 26, 2025
Public offering of shares of common stock with Series D and Series E warrants
Announced: about US$3.6M · US$0.3251 a share · Warrants at US$0.35 · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Use of proceeds: Working capital and general corporate purposes
Jun 17, 2025
Warrant exercise of series B and Series C Warrants exercised for common stock
Announced: about US$2.75M · US$0.74 a share · Warrants at US$0.74 · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners
Use of proceeds: Working capital and other general corporate purposes
May 2, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue56556556460.5K55.1K564565563565565
Gross profit-565-565-564-60.5K-55.1K-564-565-563-565-565
Research and development2.62M3.23M1.27M1.95M8.40M5.85M3.97M368.5K182.1K146.1K
Selling, general and administrative5.18M5.06M5.62M8.91M9.34M5.07M4.28M6.62M813.2K264.7K
Operating income-7.80M-8.28M-6.89M-10.9M-19.3M-10.9M-8.24M-6.99M-995.3K-410.8K
Depreciation and amortization56556556456455.1K564565563565565
EBITDA-7.80M-8.28M-6.89M-10.9M-19.2M-10.9M-8.24M-6.99M-994.7K-410.2K
Interest expense585.2K3.61M001.17M144.5K9.64K
Income before tax-7.98M-13.2M-7.00M-10.8M-19.5M-10.9M-8.59M-11.6M-1.14M-420.2K
Income tax-1.88M-502-94.1K-32.5K-76.1K-3.48M3679.64K
Net income-7.98M-13.2M-5.12M-12.7M-19.4M-10.9M-8.59M-11.6M-1.14M-420.2K
Earnings per share, basic-11.93-68.01-3.60-12.71-1.04-0.87-0.87-2.44-0.35-54.96
Earnings per share, diluted-11.93-68.01-3.60-12.71-1.04-0.87-0.87-2.44-0.35

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.88M3.75M2.83M4.00M6.06M4.40M6.78M3.87M18.2K88.0K
Receivables41.8K35.1K
Current assets6.18M4.06M3.20M4.78M6.46M5.14M7.67M4.69M27.2K141.4K
Property, plant and equipment50.4K58.1K
Goodwill249.0K249.0K0
Total assets6.67M5.04M4.74M5.73M7.47M5.49M7.68M4.70M34.5K151.5K
Accounts payable655.0K250.1K103.3K276.4K286.2K648.7K190.2K99.7K342.1K20.0K
Current liabilities1.40M975.9K653.1K1.79M2.72M1.51M539.1K258.0K1.03M255.0K
Total debt207.4K257.0K689.3K234.3K
Total liabilities1.40M975.9K653.1K2.46M3.97M1.51M539.1K258.0K1.03M255.0K
Shareholders' equity5.28M4.07M4.08M3.28M3.51M3.99M7.14M4.44M-997.6K-103.5K
Shares outstanding1.11M258.8K1.66M1.07M20.9M14.4M10.4M6.86M3.27M7.64K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-6.49M-6.92M-6.81M-11.2M-11.9M-7.63M-6.34M-2.50M-494.9K-274.4K
Capital spending-30-6.81M-5-64.6K-64.6K-64.6K-64.6K00
Free cash flow-6.49M-6.92M-6.81M-11.2M-12.0M-7.63M-6.34M-2.50M-494.9K-274.4K
Cash from investing150.0K1.50M-34.0K-350.0K-350.0K-350.0K35.1K35.1K
Cash from financing8.47M7.85M4.13M9.13M13.6M5.61M9.25M6.35M390.0K200.0K
Share buybacks-1.66K5.61M9.25M6.42M40.0K40.0K
Change in cash2.13M923.4K-1.17M-2.06M1.66M-2.38M2.91M3.85M-69.7K-74.4K

Open Financials

Cap table

Built by 6ix from Adial Pharmaceuticals, Inc’s releases · as of Aug 12, 2026

Common shares
2,625,890
Fully diluted
2,625,890

Fully diluted

LineSharesAs of
Common shares2,625,890Aug 12, 2026

Warrants and options

Lot
Warrants · expiry not stated

Share count over time

CountShares
Aug 12, 20262,625,890

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
KVP Capital Advisors, LP210K8.0%US$843KSep 30, 2026
Diadema Partners LP182K6.9%US$729KSep 30, 2026
Acuta Capital Partners, LLC130K5.0%US$521KSep 30, 2026
Jane Street53,9522.1%US$216KSep 30, 2026
Citadel29,7531.1%US$119KSep 30, 2026
XTX Topco Ltd26,7711.0%US$107KSep 30, 2026
Vanguard26,2861.0%US$105KSep 30, 2026
Geode Capital21,5460.82%US$86,398Sep 30, 2026
China Universal Asset Management Co., Ltd.12,8000.49%US$53,120Sep 30, 2026
Manchester Capital Management LLC1,9230.07%US$7,712Sep 30, 2026
All 21 holders
HolderSharesOf the companyValueAs of
Tower Research Capital LLC (TRC)1,7770.07%US$7,126Sep 30, 2026
UBS1,6880.06%US$6,769Sep 30, 2026
Barclays1,0940.04%US$4,387Sep 30, 2026
BlackRock3040.01%US$1,219Sep 30, 2026
Raffa Wealth Management, LLC83<0.01%US$333Sep 30, 2026
Morgan Stanley50<0.01%US$201Sep 30, 2026
SBI Securities Co., Ltd.45<0.01%US$180Sep 30, 2026
Northwestern Mutual Wealth Management Co30<0.01%US$120Sep 30, 2026
Caitong International Asset Management Co., Ltd9<0.01%US$36Sep 30, 2026
Wells Fargo6<0.01%US$24Sep 30, 2026
Abound Wealth Management1<0.01%US$5Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund23,5960.90%US$56,630May 31, 2026
Vanguard Extended Market Index Fund3610.01%US$924Jun 30, 2026
Fidelity Total Market Index Fund3100.01%US$744May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Coastlands Capital LP
10% owner
Buy1,233USD 2.75US$3,391Jul 16, 2026
Coastlands Capital LP
10% owner
Buy2,000USD 2.65US$5,300Jul 14, 2026
Coastlands Capital LP
10% owner
Buy1,700USD 2.70US$4,590Jul 10, 2026
Coastlands Capital LP
10% owner
Buy10,053USD 2.79US$28,048Jul 9, 2026
Coastlands Capital LP
10% owner
Buy25,000USD 2.60US$65,000Jun 29, 2026

Big stakes

StakeStakeSharesDateFiling
Coastlands Capital LP14.22%373KJun 24, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Vinay Shah
Other companies: Azora Therapeutics, Inc. (Chief Financial Officer · Since at least Nov 16, 2024); Virpax Pharmaceuticals, Inc. (Chief Financial Officer · Jun 20, 2023 – Jan 29, 2024 · Past); Aravive Inc (Chief Financial Officer · Oct 12, 2018 – Jan 24, 2022 · Past)
Chief Financial Officer · Since at least Nov 5, 2024
Cary Claiborne
Other companies: NeuroSense Therapeutics Ltd. (Board Member · Since at least Mar 18, 2026); Azora Therapeutics, Inc. (Chief Executive Officer, Director · Since at least May 29, 2025)
Chief Executive Officer, Director · Since at least Apr 7, 2026
Matt Davidson
Other companies: Azora Therapeutics, Inc. (President and CEO, Director · Since at least Jun 11, 2026)
President and CEO, Director · Since at least Jun 11, 2026
Robertson Gilliland
Other companies: Azora Therapeutics, Inc. (Director · Since at least May 23, 2023)
Director · Since at least Apr 7, 2026
Celia EconomidesChief Financial Officer · Since at least Oct 26, 2026
David RubensteinChief Scientist · Since at least Oct 16, 2026

Open People

Log in to ask 6ix AI your own questions about Adial Pharmaceuticals, Inc.